Trial record 1 of 1 for:    strive anti-jcv
Previous Study | Return to List | Next Study

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT01485003
First received: December 1, 2011
Last updated: July 10, 2015
Last verified: July 2015

December 1, 2011
July 10, 2015
January 2012
November 2018   (final data collection date for primary outcome measure)
  • Proportion of Participants who are overall disease activity-free at Months 12 and 24 [ Time Frame: Baseline and Months 12 and 24 ] [ Designated as safety issue: No ]
    Overall disease activity-free is defined as no relapses, no disability progression (RRMS), and absence of MRI disease activity (no gadolinium [gd])+ lesions, no new or enlarging T2-hyperintense lesions). A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. Sustained disability progression defined by at least a 1.0-point increase on the EDSS from a Baseline EDSS ≥1.0 that is sustained for 12 or 24 weeks, or at least a 1.5-point increase on the EDSS from a Baseline EDSS <1.0 that is sustained for 12 or 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10, with higher scores indicating more disability.
  • Proportion of participants who are clinical disease activity-free at Months 36 and 48 [ Time Frame: Baseline and Months 36 and 48 ] [ Designated as safety issue: No ]
    Clinical disease activity-free is defined as no sustained EDSS progression and no relapses at Month 36 and 48.
  • Proportion of patients who are overall disease activity-free [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
  • Proportion of patients who are clinical disease activity-free [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01485003 on ClinicalTrials.gov Archive Site
  • Identification of baseline prognostic factors that predict overall disease-free status [ Time Frame: Baseline and Month 12 ] [ Designated as safety issue: No ]
  • Identification of yearly overall disease-free response factors that predict overall disease-free status [ Time Frame: Month 12 and Month 24 ] [ Designated as safety issue: No ]
  • Clinical disease-free status [ Time Frame: Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Identification of baseline prognostic factors that predict clinical disease-free status [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  • Identification of yearly clinical disease-free response factors that predict clinical disease-free status [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Annualized Relapse Rate [ Time Frame: Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
    A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. The ARR will be calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.
  • Percentage of participants with Sustained EDSS progression [ Time Frame: Baseline and Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Sustained EDSS improvement [ Time Frame: Baseline and Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
    Sustained improvement in disability is defined as participants with Baseline EDSS of at least 2.0 who experience a ≥1.0 decrease in EDSS that is sustained for 24 weeks.
  • Change form baseline in number of new or newly enlarging T2 hyperintense lesions as assessed by MRI [ Time Frame: Baseline and Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Change from baseline in number of new T1 hypointense lesions as assessed by MRI [ Time Frame: Baseline and Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Change form baseline in number of T1 lesions with Gd-enhancing lesions as assessed by MRI [ Time Frame: Baseline and Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • MRI brain atrophy as assessed by MRI [ Time Frame: Baseline and Months 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • Change from baseline in retinal nerve fiber layer (RNFL) thickness as assessed by OCT [ Time Frame: Baseline and Month 24 and Month 48 ] [ Designated as safety issue: No ]
  • Change from baseline in low contrast visual acuity [ Time Frame: Baseline and Month 24 and Month 48 ] [ Designated as safety issue: No ]
    Low-contrast visual acuity testing captures the minimum size at which individuals can perceive letters of a particular contrast level (shade of gray on white background). Using the low-contrast Sloan letter charts at 2.5% and 1.25% low contrast levels, participants will be asked to read each of the 2 charts at a 2-meter distance using a standardized testing protocol.
  • Change from baseline in high contrast visual acuity [ Time Frame: Baseline and Month 24 and Month 48 ] [ Designated as safety issue: No ]
    High contrast acuity testing is important to help determine the smallest letters a person can read on a standardized visual acuity chart or on a card held 14 - 20 feet away. A visual acuity test is a routine part of an eye examination.
  • Cognitive impairment as assessed by change from baseline in SDMT [ Time Frame: Baseline and Months 12, 24, 36 and 48 ] [ Designated as safety issue: No ]
    SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
  • Capacity for work as assessed by change from baseline in WPAI questionnaire [ Time Frame: Baseline and Months 12, 24, 36 and 48 ] [ Designated as safety issue: No ]
    The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteeism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
  • Quality of Life as measured by MSIS-29 [ Time Frame: Baseline and Months 12, 24, 36 and 48 ] [ Designated as safety issue: No ]
    The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health.
  • Identification of baseline prognostic factors that predict overall disease-free status [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  • Identification of yearly prognostic factors that predict overall disease-free status [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
  • Clinical disease-free status [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Identification of baseline prognostic factors that predict clinical disease-free status [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  • Identification of yearly prognostic factors that predict clinical disease-free status [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Annualized Relapse Rate (ARR) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Sustained EDSS progression [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Sustained EDSS improvement [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI T2 measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI T1 measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI T1 with Gadolinium-enhancing measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • MRI brain atrophy measure [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Low Contrast Visual Acuity assessment [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Cognitive impairment as measured with the Symbol Digit Modalities Test (SDMT) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Capacity for work as measured by the Work Productivity and Activity Impairment (WPAI) questionnaire [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
  • Quality of Life as measured by the Multiple Sclerosis Impact Scale (MSIS-29) [ Time Frame: Month 48 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

The primary objective of the study is to determine which baseline and yearly response factors (clinical and para clinical) predict overall disease-free status at Month 12 and Month 24, and clinical disease-free status in subsequent Months 36 and 48. The secondary objectives are: To identify prognostic factors at Baseline that predict overall disease-free status at Month 12, and to assess if yearly overall disease-free response factors predict overall disease-free status at Month 24; To evaluate clinical disease-free status (relapse, Expanded Disability Status Scale [EDSS]) at each analysis time point of Months 12, 24, 36, and 48; To identify prognostic factors at Baseline that predict clinical disease-free status at Month 12, and to assess yearly clinical disease-free response factors that predict clinical disease-free status (relapse, EDSS) in subsequent years at Months 24, 36, and 48; To evaluate the impact of Tysabri at each analysis time point of Months 12, 24, 36, and 48 on the following: annualized relapse rate (ARR), sustained EDSS progression and improvement (24-week sustained); To evaluate the impact of Tysabri at each analysis time point of Months 12, 24, 36, and 48 on the following: magnetic resonance image (MRI) measures: T2, T1, T1 with Gadolinium (Gd), brain atrophy; To evaluate the impact of Tysabri at Month 24 and Month 48 on the following: optical coherence tomography (OCT), Low and High Contrast Visual Acuity Assessment; To evaluate the impact of Tysabri at each analysis time point of Months 12, 24, 36, and 48 on the following: cognitive impairment (Symbol Digit Modalities Test [SDMT]), capacity for work (Work Productivity and Activity Impairment Questionnaire [WPAI]), quality of life (QoL) (Multiple Sclerosis Impact Scale [MSIS-29])

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Study participants will be recruited by participating neurologists from among their MS patients who opt to begin treatment with Tysabri.

Relapsing-Remitting Multiple Sclerosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
229
November 2018
November 2018   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria ).
  • <3 year disease duration.
  • Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.
  • Anti-JCV antibody negative test within 6 months of Screening Visit.
  • Must satisfy the approved therapeutic indications for Tysabri.
  • Must be treatment-naïve to disease-modifying therapy (DMT) or have been treated with DMT (including but not limited to Avonex, Betaseron, Rebif, Copaxone, Extavia, or Gilenya) for ≤36 months total prior to date of informed consent.
  • Decision to treat with Tysabri must precede enrollment.

Key Exclusion Criteria:

  • Any prior treatment with Tysabri.
  • Anti-JCV antibody positive at any timepoint prior to the Screening Visit.
  • Contraindications to treatment with Tysabri as described in the US Prescribing Information.
  • History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.
  • History of diagnosis of Primary Progressive Multiple Sclerosis (PPM) and/or Secondary Progressive Multiple Sclerosis (SPMS).
  • Receiving immunomodulatory or immunosuppressive therapy.
  • Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).
  • Immunocompromised at the time of enrollment.
  • Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
  • Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.
  • Inability to comply with study requirements.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01485003
101MS407
Not Provided
Biogen
Biogen
Not Provided
Study Director: Medical Director Biogen
Biogen
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP